Work

Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases

Year: 2020
Type: review
Abstract: CRISPR/Cas genome editing is a simple, cost effective, and highly specific technique for introducing genetic variations. In mammalian cells, CRISPR/Cas can facilitate non-homologous end joining, homology- directed repair, and single-base exchanges. Cas9/Cas12a nuclease, dCas9 transcriptional regulators, base editors, PRIME editors and RNA editing tools are widely used in basic research. Currently, a variety of CRISPR/Cas-based therapeutics are being investigated in clinical trials. Among many new findings that have advanced the field, we highlight a few recent advances that are relevant to CRISPR/Cas-based gene therapies for monogenic human genetic diseases.
Source: Theranostics
Language: English
Open Access status: gold
Estimated APC paid: $1,671
OpenAlex ID: W3016213906
FWCI: 1.937
Cites: 100
Cited by: 157
Related to: 10